Transcriptional repression of NFKBIA triggers constitutive IKK- and proteasome-independent p65/RelA activation in senescence.
Animals
Apoptosis
/ genetics
Cell Line
Cell Proliferation
/ genetics
Cellular Senescence
/ physiology
DNA Breaks, Double-Stranded
DNA Repair
/ genetics
Female
Gene Silencing
/ physiology
Glycogen Synthase Kinase 3 beta
/ metabolism
HEK293 Cells
Humans
I-kappa B Kinase
/ metabolism
Mice
Mice, Inbred C57BL
NF-KappaB Inhibitor alpha
/ biosynthesis
Phosphorylation
Proteasome Endopeptidase Complex
/ metabolism
Transcription Factor RelA
/ metabolism
Transcription, Genetic
/ genetics
DNA damage response
IκBα
NF-κB
SASP
senescence
Journal
The EMBO journal
ISSN: 1460-2075
Titre abrégé: EMBO J
Pays: England
ID NLM: 8208664
Informations de publication
Date de publication:
15 03 2021
15 03 2021
Historique:
revised:
07
12
2020
received:
18
12
2019
accepted:
09
12
2020
pubmed:
19
1
2021
medline:
21
10
2021
entrez:
18
1
2021
Statut:
ppublish
Résumé
The IκB kinase (IKK)-NF-κB pathway is activated as part of the DNA damage response and controls both inflammation and resistance to apoptosis. How these distinct functions are achieved remained unknown. We demonstrate here that DNA double-strand breaks elicit two subsequent phases of NF-κB activation in vivo and in vitro, which are mechanistically and functionally distinct. RNA-sequencing reveals that the first-phase controls anti-apoptotic gene expression, while the second drives expression of senescence-associated secretory phenotype (SASP) genes. The rapidly activated first phase is driven by the ATM-PARP1-TRAF6-IKK cascade, which triggers proteasomal destruction of inhibitory IκBα, and is terminated through IκBα re-expression from the NFKBIA gene. The second phase, which is activated days later in senescent cells, is on the other hand independent of IKK and the proteasome. An altered phosphorylation status of NF-κB family member p65/RelA, in part mediated by GSK3β, results in transcriptional silencing of NFKBIA and IKK-independent, constitutive activation of NF-κB in senescence. Collectively, our study reveals a novel physiological mechanism of NF-κB activation with important implications for genotoxic cancer treatment.
Identifiants
pubmed: 33459422
doi: 10.15252/embj.2019104296
pmc: PMC7957429
doi:
Substances chimiques
NFKBIA protein, human
0
RELA protein, human
0
Transcription Factor RelA
0
NF-KappaB Inhibitor alpha
139874-52-5
GSK3B protein, human
EC 2.7.11.1
Glycogen Synthase Kinase 3 beta
EC 2.7.11.1
I-kappa B Kinase
EC 2.7.11.10
Proteasome Endopeptidase Complex
EC 3.4.25.1
Banques de données
GEO
['GSE158743']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e104296Informations de copyright
© 2021 The Authors. Published under the terms of the CC BY 4.0 license.
Références
Annu Rev Pathol. 2010;5:99-118
pubmed: 20078217
Genes Dev. 2012 Feb 1;26(3):203-34
pubmed: 22302935
Chembiochem. 2004 Oct 4;5(10):1348-58
pubmed: 15457532
Mol Cell Oncol. 2014 Dec 23;1(3):e963478
pubmed: 27308348
Nature. 2018 Jan 4;553(7686):96-100
pubmed: 29258294
Cell Death Differ. 2006 Aug;13(8):1351-9
pubmed: 16763616
PLoS Biol. 2008 Dec 2;6(12):2853-68
pubmed: 19053174
Cell Cycle. 2014;13(23):3628-35
pubmed: 25483060
N Engl J Med. 2011 Jul 21;365(3):277; author reply 277-8
pubmed: 21774727
Nat Cell Biol. 2013 Aug;15(8):978-90
pubmed: 23770676
Genes Dev. 2011 Oct 15;25(20):2137-46
pubmed: 21979374
Science. 2006 Feb 24;311(5764):1141-6
pubmed: 16497931
EMBO J. 1996 Dec 2;15(23):6716-26
pubmed: 8978697
Cell Cycle. 2012 Jun 15;11(12):2391-401
pubmed: 22627671
Genes Dev. 1995 Nov 15;9(22):2736-46
pubmed: 7590249
Nat Cell Biol. 2016 Sep;18(9):979-92
pubmed: 27525720
Curr Biol. 1999 Sep 9;9(17):939-45
pubmed: 10508581
Genes Dev. 2014 Jan 15;28(2):99-114
pubmed: 24449267
Science. 2011 May 20;332(6032):966-70
pubmed: 21512002
EMBO J. 2011 Apr 20;30(8):1536-48
pubmed: 21399611
Genes Dev. 2011 Oct 15;25(20):2125-36
pubmed: 21979375
Cancer Cell. 2010 Mar 16;17(3):262-72
pubmed: 20227040
J Biol Chem. 2004 Nov 26;279(48):49571-4
pubmed: 15465828
Immunol Rev. 2006 Apr;210:171-86
pubmed: 16623771
EMBO J. 1999 May 4;18(9):2401-10
pubmed: 10228155
Cell. 2008 Jun 13;133(6):1019-31
pubmed: 18555778
Immunol Rev. 2012 Mar;246(1):193-204
pubmed: 22435556
Cell Cycle. 2012 Jun 15;11(12):2231-2
pubmed: 22714590
Cell. 2008 Jun 13;133(6):1006-18
pubmed: 18555777
Nat Immunol. 2011 Jul 19;12(8):715-23
pubmed: 21772280
Sci Rep. 2016 Apr 07;6:24160
pubmed: 27052952
Nature. 2005 Aug 4;436(7051):660-5
pubmed: 16079837
J Neurooncol. 2016 Aug;129(1):139-46
pubmed: 27300524
Nat Cell Biol. 2015 Sep;17(9):1205-17
pubmed: 26280535
Cells. 2016 Mar 18;5(1):
pubmed: 26999213
Nature. 2005 Aug 4;436(7051):642
pubmed: 16079833
EMBO Rep. 2014 Jan;15(1):46-61
pubmed: 24375677
Mol Cell. 2010 Oct 8;40(1):63-74
pubmed: 20932475
Trends Immunol. 2015 Apr;36(4):217-28
pubmed: 25801910
Nat Cell Biol. 2009 Aug;11(8):973-9
pubmed: 19597488
N Engl J Med. 2011 Jul 21;365(3):276-7; author reply 277-8
pubmed: 21774728
EMBO J. 2021 Mar 15;40(6):e104296
pubmed: 33459422
Trends Biochem Sci. 2007 Jul;32(7):311-9
pubmed: 17561400
Mol Cell Biol. 1996 May;16(5):2341-9
pubmed: 8628301
EMBO J. 2018 Dec 14;37(24):
pubmed: 30467221
Mol Cell. 2009 Nov 13;36(3):365-78
pubmed: 19917246
J Biol Chem. 2001 Mar 23;276(12):8898-903
pubmed: 11114307
Nat Cell Biol. 2019 Jan;21(1):94-101
pubmed: 30602768
Development. 2001 Oct;128(19):3843-53
pubmed: 11585809
J Pathol. 2020 Jun;251(2):160-174
pubmed: 32222043
Immunol Rev. 2012 Mar;246(1):59-76
pubmed: 22435547
Mol Cell. 2007 Jul 20;27(2):183-96
pubmed: 17643369